当商品の販売は、2011年07月19日を持ちまして終了しました。
This new EP Publications report:
- Projects the number of patients with key conditions associated with
peripheral neuropathy in 2007 and 2012
- Reveals vital differences between novel compounds in development to treat
peripheral neuropathy
- Uncovers the factors and players that will drive the growth of the
emerging peripheral neuropathy market
- Predicts the commercial potential for current and upcoming drug classes in
individual country markets
- Forecasts the value (in USD) of the peripheral neuropathy market, by drug
class, by condition, and by country, in 2007 and 2012
An Emerging Worldwide Market
Currently, there are no treatments commercially available to effectively
prevent, reduce, or reverse damage to peripheral nerves, or peripheral
neuropathy. By 2012, there will be over 1.5 million individuals in the seven
major pharmaceutical markets ? U.S., France, Germany, Italy, Spain, UK, and
Japan who suffer from peripheral neuropathy caused from a wide array of factors,
including certain major medical conditions (e.g., diabetes, HIV/AIDS) and
chemical toxicity (e.g., chemotherapy treatment of cancer).
Growing Unmet Need
Peripheral neuropathy is currently managed primarily through controlling
the cause of the damage ? for diabetes and HIV/AIDS patients, this represents
treating the diseases, while for cancer patients, this means limiting doses of
chemotherapy or tolerating significant pain or loss of sensation.
Effective prevention and treatment of peripheral neuropathy would:
- Improve quality of life for patients with diabetes or HIV/AIDS by
providing relief from progressing levels of pain symptoms
- Facilitate full dosing of life-saving chemotherapeutics known to cause
peripheral neuropathy
Report Objectives & Methodology
In this report, WWMR, Inc., provides an overview of peripheral neuropathy
in the seven major pharmaeutical markets:
- U.S.
- France
- Germany
- Italy
- Spain
- UK
- Japan
Models representing patient populations and the commercial value (USD) of
this emerging market through 2012 are presented in a series of tables, charts,
and text commentary describing the important features of the key conditions
associated with peripheral neuropathy:
- Diabetes
- HIV/AIDS
- Chemotherapy treatment
Models and commentary describing the current and future peripheral neuropathy
market are based on:
- In-depth analysis of the medical literature, including treatment review
articles, medical textbooks, epidemiological studies, and clinical trials
- Thorough review of country-specific and overall trends, as well as
country-to-country comparisons, of prescriptions written for specific
conditions
- Analysis of drugs in the peripheral neuropathy drug pipeline and the
future directions in treatment
- Interviews with clinicians, including medical directors of selected pain
centers and clinicians treating peripheral neuropathy
WWMR’s Worldwide Peripheral Neuropathy report will allow pharmaceutical and
biotechnology executives to:
- Recognize the specific conditions associated with peripheral neuropathy
that have high market potential in the next 10 years
- Understand the type and level of unmet need in the peripheral neuropathy
market in the US, France, Germany, Italy, Spain, UK, and Japan
- Compare the epidemiology of peripheral neuropathy among the 7 major
pharmaceutical markets, including projected growth rates
- Target specific patient populations who will benefit most from drugs in
the peripheral neuropathy pipeline
- Anticipate upcoming competitors and product licensing opportunities
- Recognize the impact of special market dynamics, including potential
off-label usage, on product uptake forecasts
- Develop condition- and country-specific forecasts for major conditions
associated with peripheral neuropathy
TABLE OF CONTENTS
I. EXECUTIVE SUMMARY
II. INTRODUCTION AND METHODOLOGY
III. PHYSIOLOGY OF PERIPHERAL NEUROPATHY
A. Definition of Peripheral Neuropathy
- 1. Nerve Injury
- 2. Long Duration
- 3. Abnormal Sensations
- 4. Aggravation by Physiological Processes
- 5. Cellular Mechanisms of Neuropathy
B. Definition of Peripheral Neuropathic Conditions
- 1. Diabetic Neuropathy
- 2. Peripheral Neuropathy in HIV/AIDS
- 3. Chemotherapy-Induced Neuropathy
IV. EPIDEMIOLOGY - CURRENT AND FUTURE
A. Diabetic Neuropathy
- 1. Diabetic Neuropathy
- 2. Diabetes Prevalence
- 3. Diabetic Neuropathy Prevalence
- 4. Symptomatic Diabetic Neuropathy Prevalence
- 5. Diabetic Neuropathy Prevalence
- 6. Basis for Target Population Projections
- 7. Seven-Country Diabetic Neuropathy Population Projections
B. HIV/AIDS Neuropathy
- 1. HIV/AIDS Neuropathy
- 2. HIV/AIDS Incidence and Prevalence
- 3. AIDS Incidence and Prevalence
- 4. HIV/AIDS Neuropathy Prevalence
- 5. Basis for Target Population Projections
- 6. Seven-Country HIV/AIDS Neuropathy Population Projections
C. Chemotherapy-Induced Neuropathy
- 1. Chemotherapy-Treated Prevalence
- 2. Chemotherapy-Induced Neuropathy Prevalence
- 3. Basis for Target Population Projections
- 4. Seven-Country Chemotherapy-Induced Neuropathy Population Projections
V. APPROACHES FOR TREATMENT OF PERIPHERAL NEUROPATHY
A. Actual Clinical Practice and Treatment Limitations
- 1. Diabetic Neuropathy Treatment
- 2. HIV/AIDS Neuropathy Treatment
- 3. Chemotherapy-Induced Neuropathy Treatment
B. Promising New Approaches
C. Future Trends
D. Drugs in Clinical Development to Treat Peripheral Neuropathy
- 1. Current Clinical Pipeline for Peripheral Neuropathy
- 1.1 Phase III, Preregistration, Registration and Launched
- 1.1.1 Aldose Reductase Inhibitors
- 1.1.2 Carnitine Acetyltransferase Stimulants
- 1.1.3 Cannabinoid Receptor Agonists
- 1.1.4 Chemoprotectants
- 1.1.5 Protein Kinase C Inhibitors
- 1.2 Phase II
- 1.2.1 Dopamine Receptor Antagonists
- 1.2.2 Nerve Growth Factor Agonists
- 1.2.3 Interleukin-6 Agonists
- 1.2.4 Prosaposin-Derived Peptide
- 1.2.5 Prostacyclin Agonists
- 1.2.6 Prostaglandin E Agonists
- 1.2.7 Undefined Mechnism
- 1.2.8 Vascular Endothelial Growth Factor (VEGF)
- 2. Promising Drugs in Preclinical Development for Peripheral Neuropathy
- 2.1 Products in Clinical Development for Other Conditions
- 2.1.1 Copolymer Surfactant
- 2.1.2 Ion Channel Inhibitors
- 2.2 Products with No Reported Clinical Development
- 3. Discontinued or Suspended Drugs
VI. Seven-Country Peripheral Neuropathy Market Forecast
A. Forecast Methodology and Assumptions
B. Diabetic Neuropathy
- 1. Seven-Country Peripheral Neuropathy Forecast, by Class and
Country, 2007 and 2012
C. HIV / AIDS Neuropathy
- 1. Seven-Country Peripheral Neuropathy Forecast, by Condition and Country,
2007 and 2012
D. Chemotherapy-Induced Neuropathy
- 1. Seven-Country Peripheral Neuropathy Forecast, by Condition and Class,
2007 and 2012
VII. APPENDIX: ?SEVEN-COUNTRY PERIPHERAL NEUROPATHY MARKET FORCAST, BY
CLASS, CONDITION, AND COUNTRY
PARTIAL LIST OF TABLES & FIGURES
- Seven-Country Symptomatic Peripheral Neuropathy Patient Prevalence
Projections 2002 ? 2012
- Seven-Country Diabetic Neuropathy Population Projections
- Seven-Country HIV/AIDS Neuropathy Projections ? HIV Population
- Seven-Country HIV/AIDS Neuropathy Projections ? AIDS Population
- Seven-Country Chemotherapy-Induced Peripheral Neuropathy Population
Projections
- Summary by Phase of Drugs in Clinical Development for Peripheral
Neuropathy
- Seven-Country Prevalence of Peripheral Neuropathy, by Condition, 2002
- Seven-Country Market Forecast, by Class and Country, 2007 and 2012
- Seven-Country Market Forecast, by Condition and Country, 2007 and 2012
- Seven-Country Market Forecast, by Condition and Class, 2007 and 2012
